Newsroom

  • AVEO Pharmaceuticals to Present at the Cowen and Company 28th Annual Health Care Conference

    Download PDF CAMBRIDGE, MA, March 12, 2008 – AVEO Pharmaceuticals, Inc. today announced that Tuan Ha-Ngoc, president and chief executive officer, is scheduled to present at the Cowen and Company 28th Annual Health Care Conference on Wednesday, March 19, 2008 at 4:00 p.m. (ET) at the Boston Marriott Copley Place. About AVEO AVEO is a

  • AVEO Pharmaceuticals to Present at the 10th Annual BIO CEO & Investor Conference

    Download PDF CAMBRIDGE, MA, February 5, 2008 – AVEO Pharmaceuticals, Inc. today announced that Tuan Ha-Ngoc, president and chief executive officer, is scheduled to present at the 10th Annual BIO CEO & Investor Conference on Tuesday, February 12, 2008 at 1:15 p.m. (ET) at the Waldorf-Astoria in New York City. About AVEO AVEO is a

  • AVEO Initiates Phase 1b Combination Clinical Trial of Novel Triple VEGF Receptor Inhibitor AV-951 in Metastatic Renal Cell Carcinoma

    Download PDF CAMBRIDGE, MA, January 31, 2008 – AVEO Pharmaceuticals, Inc., a biotechnology company leveraging breakthrough discoveries in cancer biology to discover, develop and commercialize targeted oncology therapies, today announced that it has initiated a Phase 1b clinical trial for its lead product candidate, the novel triple VEGF receptor inhibitor AV-951, in combination with the

  • AVEO Pharmaceuticals to Present at Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference

    Download PDF CAMBRIDGE, MA, January 30, 2008 – AVEO Pharmaceuticals, Inc. today announced that Tuan Ha-Ngoc, president and chief executive officer, is scheduled to present at the Merrill Lynch Nineteenth Annual Global Pharmaceutical, Biotechnology and Medical Device Conference on Wednesday, February 6, 2008 at 1:40 p.m. (ET) at the Grand Hyatt Hotel in New York

  • AVEO Pharmaceuticals Appoints Kenneth M. Bate to Board of Directors

    Download PDF CAMBRIDGE, MA, January 3, 2008 – AVEO Pharmaceuticals, Inc., a biotechnology company leveraging breakthrough discoveries in cancer biology to discover, develop and commercialize targeted oncology therapies, today announced the appointment of Kenneth M. Bate, president and chief executive officer of NitroMed, Inc., to its Board of Directors. “We are very pleased to welcome

  • AVEO Pharmaceuticals to Present at 26th Annual JPMorgan Healthcare Conference

    Download PDF CAMBRIDGE, MA, January 2, 2008 – AVEO Pharmaceuticals, Inc. today announced that Tuan Ha-Ngoc, President and CEO of AVEO Pharmaceuticals, is scheduled to present at the 26th   Annual JPMorgan Healthcare Conference on Tuesday, January 8, 2008 at 2:30 p.m. PT at the Westin St. Francis Hotel in San Francisco. About AVEO AVEO is

  • AVEO Pharmaceuticals and Lilly Sign Collaboration for Clinical Drug Response Project

    Download PDF – Agreement Highlights Growing Interest in Novel Biology Platform that Identifies Clinical Response of Cancer Drugs- CAMBRIDGE, MA, December 4, 2007 – AVEO Pharmaceuticals, Inc., a biotechnology company leveraging breakthrough discoveries in cancer biology to discover, develop and commercialize targeted oncology therapies, today announced that it has signed a collaborative agreement with Eli

  • AVEO Pharmaceuticals to Present at Lazard Capital Markets 4th Annual Healthcare Conference

    Download PDF CAMBRIDGE, MA, November 20, 2007 – AVEO Pharmaceuticals, Inc. today announced that Tuan Ha-Ngoc, President and CEO of AVEO Pharmaceuticals, is scheduled to present at the Lazard Capital Markets 4th Annual Healthcare Conference on Tuesday, November 27, 2007 at 9:30 a.m. ET at The New York Palace Hotel in New York City. About

For media inquiries, please contact:

John F. Kouten, CEO
JFK Communications, Inc.
jfkouten@jfkhealth.com
Direct: 609-241-7352

The AVEO oncology management team comprises executives with years of oncology and pharmaceutical industry experience and expertise with a proven track record for success in bringing important new therapies to patients.